Zimmer Biomet announced that it has reached a definitive agreement to acquire Embody, a privately-held medical device company focused on soft tissue healing, for $155M at closing and up to an additional $120M subject to achieving future regulatory and commercial milestones over a three year period. The acquisition is expected to be accretive to overall revenue growth and slightly dilutive to adjusted earnings per share in 2023. The transaction is subject to customary closing conditions and is expected to be completed in February 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZBH:
- Zimmer Biomet to Acquire Embody, Inc.
- Zimmer Biomet upgraded to Outperform from Market Perform at Raymond James
- Zimmer Biomet downgraded to In Line at Evercore ISI with FY23 outlook priced in
- Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2022
- Zimmer Biomet price target raised to $130 from $116 at Citi
